Ryan White Care Hepatitis C & B Language
NATAP Webinars
Aging in Women Living with HIV
Friday, October 18h, 2024 - 12:30pm
Click here to Register
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
ID Week:
Efficacy and Safety of B/F/TAF in Black Adults With HIV Who Are Treatment Naïve: 5-Year Follow-Up From Two Phase 3 Studies
- (10/23/24)
 
ID Week:
Trends in HIV-Related Mortality Among People of Reproductive Potential in the United States HIV Deaths Plunge in Reproductive-Age US Women From 1999 to 2020
- Mark Mascolini (10/23/24)
 
ID Week:
Antiretroviral prophylaxis to prevent perinatal HIV infection in Medicaid-insured infants, 2009-2021: Over Half of HIV Infections in First Year of Life Reflect No Postnatal HIV Prophylaxis...majority Black Race
- Mark Mascolini (10/23/24)
 
ID Week:
Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe: a real-world survey
- (10/23/24)
 
ID Week:
Treatment Patterns and Healthcare Resource Utilization of Heavily Treatment Experienced People With HIV
- (10/23/24)
 
ID Week:
Impact of Pharmacoenhancers on the Pharmacokinetics and Safety of Lenacapavir in People with HIV >
- (10/23/24)
 
ID Week:
Characterization of People With HIV Who Are Virologically Suppressed With Treatment Experience Using a US Real-World Database
- (10/23/24)
 
ID Week:
Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living With HIV-1 From Pregnancy Data With Combination DTG and/or 3TC Antiretroviral Therapies
- (10/23/24)
 
ID Week:
Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort
- (10/23/24)
 
ID Week:
LAI CAB/RPV plus SC LEN Effective in PWH with Poor Long-term Adherence and INSTI or NNRTI RAMs
- (10/23/24)
 
ID Week:
Assessment of Failures of Long-Acting Cabotegravir and Rilpivirine in a Real-World Treatment Setting
- (10/23/24)
 
ID Week:
PWH Mortality Declined. Disparities Blacks, Socially Vulnerable, Older PWHL: CDC Analysis
- Mark Mascolini (10/23/24)
 
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
 
ID Week:
Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide and Pegylated-Interferon Alpha-2a
- (10/24/24)
 
ID Week:
Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 144 Interim Analysis of a Phase 3 Randomized Study
- (10/24/24)
 
More Hep D Articles...
 
Aging & Perinatally Acquired HIV
 
ID Week:
Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies
- (10/22/24)
 
ID Week:
Breast Cancer (BC) and Colorectal Cancer (CRC) Screenings among Persons with HIV (PWH): The Role of Individual and System-Level Factors on Screening Completion
- (10/22/24)
 
ID Week:
Comorbidities and Healthcare Resource Utilization Among People With HIV: Real-World Data From a Large Israeli Healthcare Provider
- (10/22/24)
 
ID Week:
T-cell Immune Exhaustion and the Atherogenic Index of Plasma in People Living with HIV on Antiretroviral Therapy
- (10/22/24)
 
More Aging & HIV Articles...
 
PrEP
 
ID Week:
Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System
- (10/24/24)
 
ID Week:
Implementation and Uptake of Long-acting Injectable PrEP at Atlanta VA Healthcare System
- (10/24/24)
 
ID Week:
Opportunities for PrEP Awareness and Engagement: A Survey among Cisgender Women Seeking Healthcare in the US
- (10/24/24)
 
ID Week:
Improving HIV Pre-exposure Prophylaxis (PrEP) among Transgender Individuals
- (10/24/24)
 
ID Week:
Integrating PrEP Services into a Gynecology Clinic in Alabama: A Qualitative Analysis of Key Determinants
- (10/24/24)
 
ID Week:
Concerns and opinions of people currently or previously on oral and long acting injectable forms of HIV preexposure prophylaxis (PrEP)
- (10/24/24)
 
ID Week:
Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide and Pegylated-Interferon Alpha-2a
- (10/24/24)
 
ID Week:
Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta in Patients With and Without Cirrhosis: Results From the Week 144 Interim Analysis of a Phase 3 Randomized Study
- (10/24/24)
 
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
ID Week:
Should HCV Be Treated in Pregnant Persons?
- (10/24/24)
 
CBO Issues Paper: "A Call for New Research in the Area of Hepatitis C" creates inordinate barrier to HCV elimination
- (08/06/24)
 
CBO Statement: "Budgetary Effects of Policies That Would Increase Hepatitis C Treatment", creates impossible unique barrier to eliminate HCV
- (08/06/24)
 
Hepatitis C Virus Reinfection Among Men Who Have Sex With Men With HIV in New York City
- (08/02/24)
 
IAS:
HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades
- (08/02/24)
 
IAS:
Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study
- Mark Mascolini (07/27/24)
 
Medicaid Expansion and Restriction Policies for Hepatitis C Treatment
- (07/20/24)
 
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
 
ID Week:
Comparison of Renal Outcomes by Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis
- (10/22/24)
 
ID Week:
High HBV Screening Rate in US Veterans Group With HIV
- Mark Mascolini (10/22/24)
 
ID Week:
HBV HIV Screening Among HIV+ US Veterans Administration
- (10/22/24)
 
ID Week:
Optimizing 2-Drug Switch HBV Screening: pilot intervention to increase HBV screening
- (10/20/24)
 
GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B
- (08/12/24)
 
IAS:
Efficacy of dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B core antibody (anti-HBc): results from the phase 3/3b GEMINI-1/-2, STAT, TANGO, and SALSA
- (07/31/24)
 
Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia - encourages earlier treatment in HBV monoinfection
- (07/10/24)
 
More Hep B Articles...
 
Fatty Liver, NAFLD, NASH
 
2nd New Fatty Liver Drug Pegozafermin in Phase 3
- (08/04/24)
 
Phase 3 Efuxifermin Fatty Liver/MASH Trial Ongoing; EASL 96 weeks HARMONY phase 2b study Results
- (08/04/24)
 
Steatotic liver disease and HIV: an agenda for 2030: 'PWH should be screened for fatty liver, steatosis'
- (07/10/24)
 
EASL:
Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
- (06/18/24)
 
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
22 February 2024 - 23 February 2024 Nairobi Kenya
https://academicmedicaleducation.com/meeting/african-workshop-hiv-women-2024
May 2-4, 2024 Atlanta, GA
https://acthiv.org/acthiv-2024-program/
https://ddw.org/
https://easl.eu/event/easl-congress-2024/
https://asm.org/Events/ASM-Microbe/Home
Munich, Germany, and virtually from 22 to 26 July 2024.
Pre-conferences will be held on 20 and 21 July.
https://www.iasociety.org/conferences/aids2024
Conference on Liver Disease in Africa (COLDA) 2024
19 September 2024 - 21 September 2024 Egypt
https://academicmedicaleducation.com/meeting/conference-liver-disease-africa-colda-2024
18 September 2024 - 20 September 2024 Liverpool, United Kingdom
https://academicmedicaleducation.com/meeting/international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs-2024
https://www.iasociety.org/conferences/hivr4p2024/registration
https://idweek.org/#
24 October 2024 - 25 October 2024 United States
Washington DC, United States
https://academicmedicaleducation.com/meeting/international-workshop-hiv-aging-2024
10-13 November 2024
https://hivglasgow.org/
San Diego, California
https://www.aasld.org/liver-meeting-tlm-2024
https://informedhorizonseducation.com/hiv-respidart-2024